SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

2.880 -0.100 (-3.36%)

Delayed Quote Updated: 10:32 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors

April 04, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Provides Company Update for Full Year 2022

March 31, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

March 29, 2023

On Wednesday, 81 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 27, 2023

On Monday, 89 stocks made new 52-week lows.

Via Benzinga

SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference

January 19, 2023

Conference to take place Feb. 6-9 in New York

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

March 24, 2023

On Friday, 469 companies hit new 52-week lows.

Via Benzinga

SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

January 18, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract ↗

January 18, 2023

SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 11, 2023

Via Benzinga

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

January 10, 2023

Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study ↗

January 10, 2023

SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)...

Via Benzinga

SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

January 09, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

January 05, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

December 29, 2022

On Thursday, 116 companies set new 52-week lows.

Via Benzinga

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

December 15, 2022

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

December 07, 2022

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022 ↗

November 29, 2022

Via Benzinga

SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

November 21, 2022

Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

November 15, 2022

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023 ↗

November 15, 2022

SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3...

Via Benzinga

SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022

November 08, 2022

Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

November 03, 2022

SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants ↗

November 03, 2022

SAB Biotherapeutics Inc (NASDAQ: SABS) presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 01, 2022

Gainers

Via Benzinga

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

October 27, 2022

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 10, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 05, 2022

Gainers

Via Benzinga

Why Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Day Session ↗

October 05, 2022

Gainers Pineapple Energy Inc. (NASDAQ: PEGY) shares jumped 104% to $2.9201. Shares of this low-float penny stock closed up about 80% on Tuesday.

Via Benzinga

Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday ↗

October 10, 2022

Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday.

Via Benzinga

Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday ↗

October 06, 2022

Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.